




# PHARMACEUTICAL 2021

Chemomab Therapeutics Ltd.  
Rank 340 of 402





# PHARMACEUTICAL 2021

Chemomab Therapeutics Ltd.  
Rank 340 of 402

The relative strengths and weaknesses of Chemomab Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Chemomab Therapeutics Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 168% points.

The company's Economic Capital Ratio, given in the ranking table, is -124%, being 172% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	6,116
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,586
Liabilities, Non-Current	16
Other Assets	51
Other Compr. Net Income	0
Other Expenses	749
Other Liabilities	0
Other Net Income	103
Other Revenues	0
Property and Equipment	12
Research and Development	3,783
Selling, General and Administrative Expense	7,180

Output Variable	Value in 1000 USD
Assets	6,179
Liabilities	2,602
Expenses	11,712
Revenues	0
Stockholders Equity	3,577
Net Income	-11,609
Comprehensive Net Income	-11,609
Economic Capital Ratio	-124%